Impact of Repeated Doses of Subcutaneous Esketamine on Acute Dissociative Symptoms in Treatment-Resistant Depression

• Autori principali: Lorena Catarina Del Sant (Autore), Luciana Maria Sarin (Autore), Ana Cecília Lucchese (Autore), Eduardo Jorge Muniz Magalhães (Autore), Marco Aurélio Tuena (Autore), Carolina Nakahira (Autore), José Alberto Del Porto (Autore), Acioly Luiz Tavares De Lacerda (Autore), Jair de Jesus Mari (Autore)
• Natura: Libro
• Pubblicazione: MDPI AG, 2022-12-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Background: Esketamine has been approved by the US Food and Drug Administration (FDA) as an adjunctive treatment for use in conjunction with an oral antidepressant for patients with treatment-resistant depression (TRD), but dissociative symptoms are common adverse effects. Methods: A retrospective a...